Barclays raised the firm’s price target on BeOne Medicines (ONC) to $409 from $405 and keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines reports Q1 adjusted EPS $3.24 vs. $1.22 last year
- BeOne Medicines raises FY26 revenue view to $6.3B-$6.5B from $6.2B-$6.4B
- AMD downgraded, Airbnb upgraded: Wall Street’s top analyst calls
- BeOne Medicines initiated with an Overweight at Wells Fargo
- BeOne Medicines: FDA grants Priority Review to sBLA for tevimbra/ziihera combo